We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Screening Test Evaluated for Sickle Cell Disease

By LabMedica International staff writers
Posted on 26 Sep 2011
Two methods used routinely for screening neonatal blood for abnormal hemoglobins have been compared with an electrophoretic method for hemolysates.

Results from a high-pressure liquid chromatography (HPLC) screening method are customarily confirmed by isoelectric electric focusing (IEF) to determine whether abnormal hemoglobinopathies are present in newborn infant's blood. More...


In a study carried out by the West Midlands Newborn Screening Laboratory (Birmingham Children’s Hospital, UK) a capillary electrophoresis system was evaluated as a possible replacement for other methods. With this technique, charged molecules are separated by their electrophoretic mobility in an alkaline buffer with a specific pH. Separation also occurs according to the electrolyte pH and electro-osmotic flow. Individual hemoglobins are separated using silica capillaries and buffers provided by the manufacturers. These hemoglobins are then detected at a wavelength of 415 nm. The resulting electrophoretograms are evaluated on screen to detect pattern abnormalities with software identifying normal and pathological patterns.

Three hundred and forty-seven blood spot specimens were analyzed first using the VARIANT newborn screening (Vnbs) HPLC method (Bio-Rad Laboratories Ltd.; Hertfordshire, UK). Any abnormal hemoglobin found was confirmed by the Resolve IEF kit supplied by Perkin-Elmer (Seer Green, UK). These specimens were then analyzed using the Capillary Neonat Hemoglobin FAST system (Sebia; Norcross, GA, USA) to compare peak identity and in a selection the percentage peak integration areas.

The Sebia-recommended sample preparation had to be modified to enable testing to be more comparable with current processes. Percentages of hemoglobins calculated from integration of areas under the peaks were compared between the Bio-Rad Vnbs HPLC and Sebia Capillarys Neonat Haemoglobin FAST system. Of the 347 blood spots tested by both HPLC and capillary electrophoresis, there were no significant differences. The Sebia Capillarys Neonat Haemoglobin FAST system can be used to screen newborns successfully for sickle cell disease in blood spots collected for newborn screening with full positive sample identification and traceability. Result analysis of newborn samples is simplified by multiple factors.

The Capillary 2 Neonat Fast system provides newborn results free of extraneous peaks. Newborn results are automatically color-coded, green for normal or red for abnormal, in order to easily distinguish abnormal results, which are also sortable and printable. All newborn results are stored electronically, easily recalled, and traceable from start to finish – true positive sample identification. The study was published for the October 2011 edition of the International Journal of Laboratory Hematology.

Related Links:

Birmingham Children’s Hospital
Bio-Rad
Sebia



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.